BigHat Biosciences

BigHat Biosciences is a biotechnology startup with a focus on developing novel protein therapeutics and utilizing an AI-guided antibody design platform. The company's mission is to enhance human health by simplifying the process of designing advanced antibody therapeutics. BigHat employs an AI-enabled experimental platform that combines a high-speed wet lab with machine learning technologies to accelerate the antibody engineering process. These capabilities have the potential to drive the development of safer and more effective treatments for challenging diseases. BigHat Biosciences, headquartered in the United States, was founded in 2019. The company recently secured a significant $75.00M Series B investment on 20 July 2022. The investors in this round include Gaingels, 8VC, AME Cloud Ventures, Amgen Ventures, Andreessen Horowitz (a16z), Quadrille Capital, Section 32, GRIDS Capital, and Bristol-Myers Squibb. The impressive lineup of investors suggests confidence in BigHat Biosciences' potential to innovate within the biotechnology industry and develop groundbreaking therapeutic solutions. With strong financial backing and a pioneering approach to drug development, BigHat Biosciences is well-positioned to make significant contributions to advancing patient care and addressing unmet medical needs.